Navigation Links
American College of Rheumatology presents recommendations for rheumatoid arthritis therapy
Date:6/3/2008

To manage the painful and incapacitating symptoms of rheumatoid arthritis (RA), a chronic, inflammatory joint disease, the majority of patients rely on disease-modifying antirheumatic drugs (DMARDs). In addition to trusted nonbiologic DMARDs, a number of biologic agents now promise to improve treatment for RA. The American College of Rheumatology (ACR), respected worldwide for its devotion to fostering excellence in patient care, has not updated recommendations for non-biologic DMARDs since 2002 and has not previously developed recommendations for biologic agents. In view of that, ACR decided it was time for a major re-evaluation of the use of DMARD therapy in rheumatoid arthritis.

Under the guidance of a Core Expert Panel of clinicians and methodologists and based on a systematic review of the scientific evidence, a second group of internationally recognized clinicians, methodologists, and patient representatives with extensive expertise in the use of nonbiologic and biologic DMARDs developed these recommendations for the ACR and the results of their work will be presented in the June 2008 issue of Arthritis Care & Research (www.interscience.wiley.com/journal/arthritis). These recommendations on the use of non-biologic and biologic DMARDs in RA address 5 key areas pre-specified by the ACR: indications for use, monitoring for side-effects, assessing the clinical response, screening for tuberculosis (a risk factor associated with biologic DMARDs), and under certain circumstances (i.e. high disease activity) the roles of cost and patient preference in choosing biologic agents. When developing these recommendations, RA disease duration, disease severity, and prognostic features were also considered.

"These recommendations were developed for specialist clinicians familiar with assessing RA disease activity and disease severity," notes Kenneth Saag, M.D., Professor of Medicine and Epidemiology at The University of Alabama at Birmingham, who co-led the project . "Applying these recommendations to clinical practice requires individualized patient assessment and clinical decision-making. The recommendations developed are not intended to be used in a 'cookbook' or prescriptive manner or to limit a physicians clinical judgment, but rather to provide guidance based on clinical evidence and expert panel input."

The ACR 2008 recommendations for nonbiologic and biologic DMARD use in RA include:

  • Initiating methotrexate or leflunomide therapy was recommended for most RA patients.

  • Methotrexate plus hydroxychloroquine was endorsed for patients with moderate to high disease activity.

  • The triple DMARD combination of methotrexate plus hydroxychloroquine plus sulfasalazine for patients with poor prognostic features and moderate to high levels of disease activity.

  • Prescribing anti-TNF agents -- etanercept, infliximab, or adalimumab -- along with methotrexate in early RA (less than 3 months) only for patients with high disease activity who had never received DMARDs. In intermediate- and longer-duration RA, anti-TNF agents were recommended for patients who had failed to respond adequately to methotrexate therapy.

  • Reserving the fusion protein abatacept and the B-cell antibody(rituximab) for patients with at least moderate disease activity and poor disease prognosis for whom methotrexate in combination with or sequential administration of other nonbiologic DMARDs led to an inadequate response.

  • Avoiding the initiation or resumption of treatment with methotrexate, leflunomide, or biologic agents for patients with active bacterial infection, active herpes-zoster viral infection, active or latent tuberculosis, or acute or chronic hepatitis B or C.

  • Not prescribing anti-TNF agents to patients with a history of heart failure, with a history of lymphoma, or with multiple sclerosis or demyelinating disorders.

  • Avoiding the initiation or resumption of methotrexate, leflunomide, or minocycline for RA patients planning for pregnancy and throughout the duration of pregnancy and breastfeeding.

"These recommendations are extensive but not comprehensive," Dr. Saag acknowledges, "and it is intended that they will be regularly updated to reflect the rapidly growing scientific evidence in this area along with changing practice patterns in rheumatology."


'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. American Italian Pasta Company Extends Line of Healthier Pastas With Heartland(R) Perfect Balance
2. American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives
3. American Academy of Pediatrics Launches 2008 National Art Contest for Children
4. Animal Dermatology Clinic - San Diego Announces Dr. Brett Wildermuth, DVM, Achieves Diplomate Status With the American College of Veterinary Dermatology
5. Isis Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
6. American Oriental Bioengineering Announces US$75 Million Share Repurchase Program
7. Indiana University research at the American College of Sports Medicine annual conference
8. Jeff Bailet, M.D., Appointed to American Medical Associations Advisory Committee
9. American Lung Association of Iowa: Summer Camp Helps Kids With Asthma
10. Delisting Notification Received from the American Stock Exchange
11. American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Dr. David ... in Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated ... is an online directory that recognizes local physicians and dentists who have earned ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for ... expert sit stand solutions representative to the Minneapolis Home and Garden Show which is ... event that is garnering national attention is the Minneapolis Convention Center. , From ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company ... announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology: